8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.

Abdel Rahman GAN, Mohamed AF

Bioeffects Seen

Authors not listed · 2025

Share:

Database error: this pharmaceutical study contains no EMF research and shouldn't influence EMF health decisions.

Plain English Summary

Summary written for general audiences

This study appears to be misclassified in an EMF database, as it actually examined Factor XIa inhibitor drugs for preventing blood clots in atrial fibrillation patients. Researchers analyzed three clinical trials comparing these new anticoagulant medications to standard blood thinners. The study found no EMF-related health effects because it wasn't an EMF study at all.

Why This Matters

This appears to be a database classification error. The study examines pharmaceutical anticoagulants for heart rhythm disorders, not electromagnetic field exposures. While such mix-ups might seem trivial, they highlight a broader issue in EMF research: the importance of rigorous study categorization and peer review. When genuine EMF health studies get lost among unrelated research, it becomes harder for both scientists and the public to access the real evidence about electromagnetic exposures. This kind of database contamination can undermine confidence in EMF research databases and make it more difficult to identify legitimate patterns in the scientific literature. What this means for you is the need to verify that EMF studies actually involve electromagnetic field exposures before drawing any health conclusions.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2025). Abdel Rahman GAN, Mohamed AF.
Show BibTeX
@article{abdel_rahman_gan_mohamed_af_ce3945,
  author = {Unknown},
  title = {Abdel Rahman GAN, Mohamed AF},
  year = {2025},
  doi = {10.1161/circ.152.suppl_3.4361654},
  
}

Quick Questions About This Study

This appears to be a database classification error. The study examines blood-thinning medications for heart patients, not electromagnetic field exposures, and contains no EMF-related research or findings.
No, Factor XIa inhibitors are pharmaceutical drugs that prevent blood clots. This cardiovascular medication research has no connection to electromagnetic field exposure or EMF health effects.
No, pharmaceutical studies of blood-thinning drugs provide no relevant information about electromagnetic field health effects. EMF research requires actual electromagnetic exposure measurements and biological endpoints.
Nothing. Asundexian is a pharmaceutical drug being tested for preventing blood clots in heart patients. The stroke risk findings relate to medication dosing, not electromagnetic field exposure.
This study provides no EMF exposure data to inform such decisions. Any medication choices should be based on medical consultation with healthcare providers, not misclassified research studies.